Pharmaceutical Contract Development & Manufacturing (CDMO) / Nanotechnology Services
Strategic Profile
Nanoform's competitive advantage lies in its patented, scalable CESS technology and emerging Nanoform Biologics platform for high-dose subcutaneous delivery of large molecules. The company positions itself to reduce clinical trial attrition and extend product lifecycles while serving a high-value pharma market where formulation enhancement drives significant differentiation.
Cyborg Score Rationale
While Nanoform operates in a high-value pharma niche with differentiated technology, the company faces significant profitability challenges with 2024 losses of €23.43M against modest revenue of €3.66M. Early-stage adoption and execution risk remain, though recent advances in biologics applications show strategic promise.
Top Insights
Core CESS technology enables creation of nanoparticles as small as 10nm, directly addressing bioavailability challenges for poorly soluble pharmaceutical compounds
Emerging Nanoform Biologics platform demonstrates high-dose subcutaneous delivery capabilities, expanding addressable market beyond small molecules into large molecule therapeutics
June 2025 achievement of nanotrastuzumab (antibody nanoformulation) validates platform capability for major pharma applications and potential lifecycle extension partnerships
Significant cash burn (losses exceed revenue by 6x) indicates pre-commercial phase with limited recurring revenue generation to date
Named Competitors
Particle Engineering Services — Global CDMO with extensive formulation services
Formulation & Delivery — Large CDMO with particle engineering capabilities
Specialty Formulation — Contract manufacturer with formulation services
Recent Developments
(June 2025) Successful development of nanotrastuzumab formulation for subcutaneous injection, demonstrating platform capability for biologics applications
(2024) Revenue growth of 42.7% to €3.66M, though losses increased 12.9% to €23.43M, indicating scaling challenges
(2025) Presentation of nanoformed trastuzumab developments at industry summits, advancing visibility for biologics platform
Open the full interactive Nanoform Finland Oyj report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.